novo nordisk semaglutide patent Off-patent in 2026: the next revolution in anti-obesity medications Novo Nordisk to lose patent

However, a sudden decrease in fat mass can impact estrogen production, leading to temporary menstrual irregularities

Your provider may recommend: Shorter time at the 2.5 mg initiation dose (3 weeks instead of 4) More aggressive titration to reach therapeutic levels sooner Targeting higher maintenance doses (12.5 to 15 mg) from the outset Closer monitoring of side effects to balance speed with tolerance The microdosing alternative for sensitive switchers Not everyone needs or wants to follow the standard titration

What day should I inject

Avoid alcohol, as it can cause fluctuations in blood sugar and worsen side effects